RIGL NASDAQ
Rigel Pharmaceuticals, Inc.
1W: -2.1%
1M: -4.6%
3M: +17.1%
YTD: +12.7%
1Y: +67.4%
3Y: +324.8%
5Y: +26.1%
$47.15
+0.18 (+0.38%)
Weekly Expected Move ±4.4%
$43
$45
$47
$49
$51
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (64)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL
18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment Board
Hsbc Holdings PLC Takes $745,000 Position in Rigel Pharmaceuticals, Inc. $RIGL
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL
Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy
Rigel Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Rigel projects $275M-$290M 2026 total revenue while restructuring debt and regaining RIPK1 rights
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Rigel Pharmaceuticals GAAP EPS of $0.44 misses by $0.28, revenue of $58.8M misses by $3.6M
Rigel Reports First Quarter 2026 Financial Results
Earnings Scheduled For May 5, 2026
Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Eli Lilly terminates license agreement with Rigel over ocadusertib
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Moderate Buy” from Brokerages
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Top 10 undervalued small-cap stocks with high growth grades
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
What is HC Wainwright’s Forecast for RIGL Q3 Earnings?
Equities Analysts Issue Forecasts for RIGL Q1 Earnings
Rigel Pharma slides as falling contract revenue to drive contraction
12 Health Care Stocks Moving In Wednesday's Intraday Session
Nasdaq Surges Over 1%; ISM Services PMI Tops Views
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of “Hold” from Brokerages
Rigel Pharma (RIGL) Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Earnings Summary: Rigel Pharmaceuticals Q4
Rigel Pharmaceuticals GAAP EPS of $13.54 beats by $12.31, revenue of $69.8M beats by $1.1M
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
Here are the major earnings after the close Tuesday
Earnings Scheduled For March 3, 2026
Rigel Pharmaceuticals Q4 2025 Earnings Preview
A Preview Of Rigel Pharmaceuticals's Earnings
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL
Rigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Provides Business Update and 2026 Outlook
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rigel Pharma: Formulating A Game Plan For 2026
Rigel Pharmaceuticals, Inc. $RIGL Position Boosted by Squarepoint Ops LLC
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of “Hold” from Analysts
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?
Rigel Pharma: Q3 Earnings Showcase Robust Growth
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference